Eiropas Savienība - latviešu - EMA (European Medicines Agency)

camurus ab - buprenorphine - ar opioīdiem saistītas slimības - other nervous system drugs - opioīdu atkarības ārstēšanā ietvaros medicīnisko, sociālo un psiholoģisko ārstēšanu. Ārstēšana ir paredzēts lietošanai pieaugušajiem un pusaudžiem vecumā līdz 16 gadiem vai vairāk.

Latvija - latviešu - Zāļu valsts aģentūra

fresenius kabi ab, sweden - sojas pupiņu eļcļca, attīrīta - emulsija infūzijām - 20%

Latvija - latviešu - Zāļu valsts aģentūra

fresenius kabi ab, sweden - kalcija chloridum, magnija sulfas, glikozi, soiae naftas raffinatum, alaninum, argininum, methioninum, leucinum, skābes asparticum, skābes glutamicum, glycinum, histidinum, isoleucinum, lysinum, phenylalaninum, prolinum, serinum, threoninum, tryptophanum, tyrosinum, valinum, natrii glycerophosphas, kalii chloridum, natrii acetas - emulsija infūzijām

Latvija - latviešu - Zāļu valsts aģentūra

astrazeneca ab, sweden - budesonidum, formoteroli fumaras dihydricus - inhalācijas pulveris - 160 μg/4,5 μg/inhalācijā

Latvija - latviešu - Zāļu valsts aģentūra

astrazeneca ab, sweden - budesonidum, formoteroli fumaras dihydricus - inhalācijas pulveris - 80 μg/4,5 μg/inhalācijā

Latvija - latviešu - Zāļu valsts aģentūra

astrazeneca ab, sweden - budesonidum, formoteroli fumaras dihydricus - inhalācijas pulveris - 320 μg/9 μg/inhalācijā

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - karcinoma, nesīkšūnu plaušas - antineoplastiski līdzekļi - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastiski līdzekļi - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

octapharma ab - simoctocog alfa - a hemofīlija - blood coagulation factors - asiņošanas ārstēšana un profilakse pacientiem ar hemofiliju a (iedzimtais viii faktora deficīts). nuwiq var izmantot visās vecuma grupās.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - karcinoma, nesīkšūnu plaušas - antineoplastiski līdzekļi - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.